ADAR1 Regulation of Viro-Immunotherapy in Malignant Pleural Mesothelioma
Abstract
Mesothelioma remains an incurable cancer with current therapy. The response rate to the best chemotherapy is only 40%. Similarly, the response rate to state of the art immunotherapy with niovlumab and ipiluminab is only slightly better. Very few patients live longer than 1 year after diagnosis. New therapeutic approaches are needed. Novel therapy that enhances immunotherapy is an innovative approach. In addition, an oncolytic vesicular stomatitis virus combined with immunotherapy becomes an ideal novel therapeutic approach to treating mesothelioma. The vesicular stomatitis virus (VSV) has already been safely used in patients. In this study, we intend to develop a novel therapeutic approach with a combination of altering a protein, ADAR1, that will make mesothelioma cancers more susceptible to treatment with immunotherapy. In addition, we will add the virus treatment (VSV) to aid in the immune response to treat this lethal cancer. If successful, this will lead to a totally novel and hopefully effective treatment for mesothelioma.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Dec 28, 2022
- Source ID
- W81XWH2210537
Entities
People
- Robert Kratzke
Organizations
- United States Army
- University of Minnesota